The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Cytadren     3-(4-aminophenyl)-3-ethyl- piperidine-2,6...

Synonyms: Orimeten, Elipten, AG-1, Prestwick_243, CHEMBL488, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cytadren


Psychiatry related information on Cytadren


High impact information on Cytadren


Chemical compound and disease context of Cytadren


Biological context of Cytadren


Anatomical context of Cytadren


Associations of Cytadren with other chemical compounds


Gene context of Cytadren


Analytical, diagnostic and therapeutic context of Cytadren


  1. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W.D., Linehan, W.M., Myers, C.E. J. Natl. Cancer Inst. (1994) [Pubmed]
  2. Aminoglutethimide, alveolar damage, and hemorrhage. Rodman, D.M., Hanley, M., Parsons, P. Ann. Intern. Med. (1986) [Pubmed]
  3. Aminoglutethimide and cholestasis. Perrault, D.J., Domovitch, E. Ann. Intern. Med. (1984) [Pubmed]
  4. Cholestatic jaundice and aminoglutethimide. Gerber, S.B., Miller, K.B. Ann. Intern. Med. (1982) [Pubmed]
  5. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Kaye, S.B., Woods, R.L., Fox, R.M., Coates, A.S., Tattersall, M.H. Cancer Res. (1982) [Pubmed]
  6. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Smith, I.E., Harris, A.L., Morgan, M., Gazet, J.C., McKinna, J.A. Cancer Res. (1982) [Pubmed]
  7. Antiglucocorticoid therapies in major depression: a review. Murphy, B.E. Psychoneuroendocrinology (1997) [Pubmed]
  8. Aminoglutethimide, a corticosteroid synthesis inhibitor, facilitates brain stimulation reward in food-restricted rats: an investigation of underlying mechanisms. Abrahamsen, G.C., Kandawire, M.J., Carr, K.D. Psychopharmacology (Berl.) (1997) [Pubmed]
  9. Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. Murray, F.T., Santner, S., Samojlik, E., Santen, R.J. Journal of clinical pharmacology. (1979) [Pubmed]
  10. Development of tolerance to the CNS effects of aminoglutethimide in mice. Ahmad, B., Nicholls, P.J. Eur. J. Pharmacol. (1990) [Pubmed]
  11. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. Santen, R.J., Worgul, T.J., Samojlik, E., Interrante, A., Boucher, A.E., Lipton, A., Harvey, H.A., White, D.S., Smart, E., Cox, C., Wells, S.A. N. Engl. J. Med. (1981) [Pubmed]
  12. Low-dose aminoglutethimide and aromatase inhibition. Dowsett, M., Jeffcoate, S.L., Santner, S., Santen, R.J., Stuart-Harris, R., Smith, I.E. Lancet (1985) [Pubmed]
  13. Low-dose aminoglutethimide in treatment of advanced breast cancer. Stuart-Harris, R., Dowsett, M., Bozek, T., McKinna, J.A., Gazet, J.C., Jeffcoate, S.L., Kurkure, A., Carr, L., Smith, I.E. Lancet (1984) [Pubmed]
  14. Detection of P450c17-independent pathways for dehydroepiandrosterone (DHEA) biosynthesis in brain glial tumor cells. Cascio, C., Prasad, V.V., Lin, Y.Y., Lieberman, S., Papadopoulos, V. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  15. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Papadopoulos, V., Guarneri, P., Kreuger, K.E., Guidotti, A., Costa, E. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  16. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Powles, T.J., Ashley, S., Ford, H.T., Gazet, J.C., Nash, A.G., Neville, A.M., Coombes, R.C. Lancet (1984) [Pubmed]
  17. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses. Santen, R.J., Worgul, T.J., Samojlik, E., Boucher, A.E., Lipton, A., Harvey, H. Cancer Res. (1982) [Pubmed]
  18. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. Ahlgren, J.D., Ellison, N.M., Gottlieb, R.J., Laluna, F., Lokich, J.J., Sinclair, P.R., Ueno, W., Wampler, G.L., Yeung, K.Y., Alt, D. J. Clin. Oncol. (1993) [Pubmed]
  19. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. Dawson, N., Figg, W.D., Brawley, O.W., Bergan, R., Cooper, M.R., Senderowicz, A., Headlee, D., Steinberg, S.M., Sutherland, M., Patronas, N., Sausville, E., Linehan, W.M., Reed, E., Sartor, O. Clin. Cancer Res. (1998) [Pubmed]
  20. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Lien, E.A., Anker, G., Lønning, P.E., Solheim, E., Ueland, P.M. Cancer Res. (1990) [Pubmed]
  21. Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Wilkinson, J.R., Williams, J.C., Singh, D., Goss, P.E., Easton, D., Coombes, R.C. Cancer Res. (1986) [Pubmed]
  22. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. New, M.I., Peterson, R.E., Saenger, P., Levine, L.S. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  23. Metabolism of steroid-modifying anticancer agents. Robinson, S.P., Jordan, V.C. Pharmacol. Ther. (1988) [Pubmed]
  24. Intramitochondrial movement of adrenal sterol carrier protein with cholesterol in response to corticotropin. Conneely, O.M., Headon, D.R., Olson, C.D., Ungar, F., Dempsey, M.E. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  25. Glucocorticoid stimulation of ileal Na+ absorptive cell brush border Na+/H+ exchange and association with an increase in message for NHE-3, an epithelial Na+/H+ exchanger isoform. Yun, C.H., Gurubhagavatula, S., Levine, S.A., Montgomery, J.L., Brant, S.R., Cohen, M.E., Cragoe, E.J., Pouyssegur, J., Tse, C.M., Donowitz, M. J. Biol. Chem. (1993) [Pubmed]
  26. Resistance of the ovary to blockade of aromatization with aminoglutethimide. Santen, R.J., Samojlik, E., Wells, S.A. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  27. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Lønning, P.E., Kvinnsland, S. Drugs (1988) [Pubmed]
  28. Aminoglutethimide augments follicle-stimulating hormone-induced aromatase activity in cultured porcine granulosa cells. Chan, W.K., Tan, C.H. Endocrinology (1988) [Pubmed]
  29. Regulation of intramitochondrial cholesterol transfer to side-chain cleavage cytochrome P-450 in rat adrenal gland. Privalle, C.T., Crivello, J.F., Jefcoate, C.R. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  30. Luteinizing hormone receptor appearance in cultured porcine granulosa cells requires continual presence of follicle-stimulating hormone. Segaloff, D.L., Limbird, L.E. Proc. Natl. Acad. Sci. U.S.A. (1983) [Pubmed]
  31. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. Schmid, M., Jakesz, R., Samonigg, H., Kubista, E., Gnant, M., Menzel, C., Seifert, M., Haider, K., Taucher, S., Mlineritsch, B., Steindorfer, P., Kwasny, W., Stierer, M., Tausch, C., Fridrik, M., Wette, V., Steger, G., Hausmaninger, H. J. Clin. Oncol. (2003) [Pubmed]
  32. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model. Brodie, A.M., Garrett, W.M., Hendrickson, J.R., Tsai-Morris, C.H. Cancer Res. (1982) [Pubmed]
  33. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors. Wing, L.Y., Garrett, W.M., Brodie, A.M. Cancer Res. (1985) [Pubmed]
  34. Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. Lefrançois-Martinez, A.M., Tournaire, C., Martinez, A., Berger, M., Daoudal, S., Tritsch, D., Veyssière, G., Jean, C. J. Biol. Chem. (1999) [Pubmed]
  35. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Frost, V.J., Helle, S.I., Lønning, P.E., van der Stappen, J.W., Holly, J.M. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  36. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. Noguchi, T., Kitawaki, J., Tamura, T., Kim, T., Kanno, H., Yamamoto, T., Okada, H. J. Steroid Biochem. Mol. Biol. (1993) [Pubmed]
  37. Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. Fassnacht, M., Beuschlein, F., Vay, S., Mora, P., Allolio, B., Reincke, M. J. Endocrinol. (1998) [Pubmed]
  38. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Romeo, D., Caroti, C., Farris, A., Cruciani, G., Villa, E., Schieppati, G., Mustacchi, G. J. Clin. Oncol. (2001) [Pubmed]
  39. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Santen, R.J., Santner, S.J., Tilsen-Mallett, N., Rosen, H.R., Samojlik, E., Veldhuis, J.D. Cancer Res. (1982) [Pubmed]
  40. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Wells, S.A., Santen, R.J., Lipton, A., Haagensen, D.E., Ruby, E.J., Harvey, H., Dilley, W.G. Ann. Surg. (1978) [Pubmed]
  41. Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. Figg, W.D., Thibault, A., Sartor, A.O., Mays, D., Headlee, D., Calis, K.A., Cooper, M.R. Arch. Intern. Med. (1994) [Pubmed]
WikiGenes - Universities